💰SWF – Sovereign Wealth Fund

💰SWF – Sovereign Wealth Fund

NZ Super Resumes Government Contributions

The New Zealand Superannuation Fund (NZ Super) has resumed receiving contributions from the New Zealand government in the face of rising obligations as an increasing proportion of the country’s population approaches retirement.

According to a statement released by the fund’s managing Board of Guardians, the government plans on investing US$ 5.3 billion into NZ Super between now and June of 2022, with the first payment scheduled for December 15, 2017.

https://www.swfinstitute.org/swf-news/nz-super-resumes-government-contributions/

iZettle Raises US$ 47 Million in Series E, Prepares for 2018 Listing.

Card transaction platform iZettle AB has raised another US$ 47 million in Series E funding,

this time with new backing from Sweden’s AP4 and early-stage venture capital firm Dawn Capital.

Previous investors in the Stockholm-based payments business include

American Express,

MasterCard,

Intel,

Spain’s Santander Group.

With US$ 235 million in equity to date, iZettle is quickly approaching an estimated valuation of US$ 1 billion.

https://www.swfinstitute.org/swf-news/izettle-raises-us-47-million-in-series-e-prepares-for-2018-listing/

Sweden’s iZettle raises $47M to expand mPOS business | Mobile Payments Today

https://www.mobilepaymentstoday.com/news/swedens-izettle-raises-47m-to-expand-mpos-business/

 

Gaw Capital Sells Cross Tower Shanghai Building

Hong Kong-based Gaw Capital Partners has agreed to sell the Cross Tower, a 24-storey commercial building in Shanghai, to World Union Investment Management, for 2.66 billion RMB (US$ 402 million). The tower is located in the Huangpu district.

https://www.swfinstitute.org/swf-news/swfi-first-read-december-15-2017/

RDIF Portfolio Company Geopharm Plans to Increase Insulin Production

Russia-based Geopharm is a portfolio company of the Russian Direct Investment Fund (RDIF). Geopharm signed a special investment agreement with the City of St. Petersburg, Russia. Geopharm plans to invest more than 3.3 billion rubles in building a complex to meet insulin production demands.

https://www.swfinstitute.org/swf-news/swfi-first-read-december-15-2017/